Postes actifs de Robert J. Hickey
Sociétés | Poste | Début | Fin |
---|---|---|---|
CS-Keys, Inc.
CS-Keys, Inc. Medical SpecialtiesHealth Technology CS-Keys is the leader in discovery and development of cancer diagnostics based on the science of the DNA Synthesome. As the greatest potential for reducing mortality of cancer lies in the detection of asymptomatic, early stage disease, as well as for residual disease after treatment, the discovery of new markers for this purpose holds significant promise. CS-Keys patented caPCNA antibody may be a powerful ally in helping pathologists achieve this objective. CS-Keys, Inc. is a private, Indianapolis-based biotechnology company focused on the discovery and development of 3rd generation cancer-associated biomarkers using proteomics. These biomarkers may be used to create products to enhance the diagnosis and treatment of patients with cancer. CS-Keys was founded in early 2006 to develop and commercialize products based on the founders research and licensed from Indiana University. | Fondateur | 05/08/2009 | - |
Corporate Officer/Principal | 01/01/2006 | 05/08/2009 | |
Indiana University | Corporate Officer/Principal | - | - |
RLL LLC
RLL LLC BiotechnologyHealth Technology RLL LLC engages in the provision of biotechnology services. The company is headquartered in Lutherville, MD. | Directeur/Membre du Conseil | - | - |
Historique de carrière de Robert J. Hickey
Statistiques
Internationale
Etats-Unis | 4 |
Opérationnelle
Corporate Officer/Principal | 2 |
Founder | 1 |
Director/Board Member | 1 |
Sectorielle
Health Technology | 3 |
Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 2 |
---|---|
CS-Keys, Inc.
CS-Keys, Inc. Medical SpecialtiesHealth Technology CS-Keys is the leader in discovery and development of cancer diagnostics based on the science of the DNA Synthesome. As the greatest potential for reducing mortality of cancer lies in the detection of asymptomatic, early stage disease, as well as for residual disease after treatment, the discovery of new markers for this purpose holds significant promise. CS-Keys patented caPCNA antibody may be a powerful ally in helping pathologists achieve this objective. CS-Keys, Inc. is a private, Indianapolis-based biotechnology company focused on the discovery and development of 3rd generation cancer-associated biomarkers using proteomics. These biomarkers may be used to create products to enhance the diagnosis and treatment of patients with cancer. CS-Keys was founded in early 2006 to develop and commercialize products based on the founders research and licensed from Indiana University. | Health Technology |
RLL LLC
RLL LLC BiotechnologyHealth Technology RLL LLC engages in the provision of biotechnology services. The company is headquartered in Lutherville, MD. | Health Technology |
- Bourse
- Insiders
- Robert J. Hickey
- Expérience